{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:47:25Z","timestamp":1769575645148,"version":"3.49.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019887","name":"GW Research","doi-asserted-by":"publisher","award":["2016-T1-\/BMD-1060"],"award-info":[{"award-number":["2016-T1-\/BMD-1060"]}],"id":[{"id":"10.13039\/100019887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019887","name":"GW Research","doi-asserted-by":"publisher","award":["GWCRI09119"],"award-info":[{"award-number":["GWCRI09119"]}],"id":[{"id":"10.13039\/100019887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["15-0310"],"award-info":[{"award-number":["15-0310"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS-PS1600629"],"award-info":[{"award-number":["FIS-PS1600629"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bcp.2018.08.014","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T18:48:45Z","timestamp":1534358925000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders"],"prefix":"10.1016","volume":"157","author":[{"given":"Onintza","family":"Sagredo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Palazuelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gutierrez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Satta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael","family":"Galve-Roperh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Mart\u00ednez-Orgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.08.014_b0005","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrn3937","article-title":"Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy","volume":"16","author":"Soltesz","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease","volume":"134","author":"Bl\u00e1zquez","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2018.08.014_b0015","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2018.08.014_b0020","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","article-title":"Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of huntington\u2019s disease","volume":"32","author":"Bouchard","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington\u2019s disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.bcp.2018.08.014_b0030","first-page":"85","article-title":"Estrategias de neuroprotecci\u00f3n en el reci\u00e9n nacido","volume":"12","author":"Mart\u00ednez-Orgado","year":"2014","journal-title":"An Pediatr Contin."},{"key":"10.1016\/j.bcp.2018.08.014_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2014.00359","article-title":"Barrier mechanisms in neonatal stroke","volume":"8","author":"Kratzer","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/GRF.0b013e318187087c","article-title":"Causative factors in cerebral palsy","volume":"51","author":"Nelson","year":"2008","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.bcp.2018.08.014_b0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clp.2016.04.002","article-title":"Pathophysiology of Birth Asphyxia","volume":"43","author":"Rainaldi","year":"2016","journal-title":"Clin. Perinatol."},{"key":"10.1016\/j.bcp.2018.08.014_b0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1474-4422(11)70016-3","article-title":"Treatment advances in neonatal neuroprotection and neurointensive care","volume":"10","author":"Johnston","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2018.08.014_b0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/157488907780832724","article-title":"The seek of neuroprotection: introducing cannabinoids","volume":"2","author":"Mart\u00ednez-Orgado","year":"2007","journal-title":"Recent Pat. CNS Drug Discovery"},{"key":"10.1016\/j.bcp.2018.08.014_b0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1523\/JNEUROSCI.22-02-00455.2002","article-title":"Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia","volume":"22","author":"Back","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0065","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijdevneu.2011.02.012","article-title":"The developing oligodendrocyte: key cellular target in brain injury in the premature infant","volume":"29","author":"Volpe","year":"2010","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pneurobio.2004.02.001","article-title":"Astrocyte apoptosis: implications for neuroprotection","volume":"72","author":"Takuma","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bcp.2018.08.014_b0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/187152411796011303","article-title":"Astrocytes: targets for Neuroprotection in Stroke","volume":"11","author":"Barreto","year":"2011","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.bcp.2018.08.014_b0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/j.semperi.2016.09.007","article-title":"Outcomes in childhood following therapeutic hypothermia for neonatal hypoxic-ischemic encephalopathy (HIE)","volume":"40","author":"Natarajan","year":"2016","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.bcp.2018.08.014_b0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clp.2013.09.004","article-title":"Pharmacologic Neuroprotective Strategies in Neonatal Brain Injury","volume":"41","author":"Juul","year":"2014","journal-title":"Clin. Perinatol."},{"key":"10.1016\/j.bcp.2018.08.014_b0090","first-page":"302","article-title":"Mechoulam_2003","volume":"80","author":"Mechoulam","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bcp.2018.08.014_b0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.plipres.2011.01.001","article-title":"Is lipid signaling through cannabinoid 2 receptors part of a protective system?","volume":"50","author":"Pacher","year":"2011","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0100","article-title":"Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration","volume":"1415\u20131427","author":"Hansen","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2018.08.014_b0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.014_b0110","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.1523\/JNEUROSCI.21-22-08765.2001","article-title":"Exogenous anandamide protects rat brain against acute neuronal injury in vivo","volume":"21","author":"van der Stelt","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0115","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1523\/JNEUROSCI.21-17-06475.2001","article-title":"Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity","volume":"21","author":"van der Stelt","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.bjp.0706755","article-title":"Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage","volume":"148","author":"Shouman","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1203\/01.pdr.0000228839.00122.6c","article-title":"Characterization of the Neuroprotective Effect of the Cannabinoid Agonist WIN -55212 in an In Vitro Model of Hypoxic-Ischemic Brain Damage in Newborn Rats","volume":"60","author":"Fernandez-Lopez","year":"2006","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0130","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1523\/JNEUROSCI.19-08-02987.1999","article-title":"Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures","volume":"19","author":"Nagayama","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3940(99)00922-2","article-title":"Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats","volume":"278","author":"Sinor","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2018.08.014_b0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ana.410090206","article-title":"The influence of immaturity on hypoxic-ischemic brain damage in the rat","volume":"9","author":"Rice","year":"1981","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2018.08.014_b0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1203\/PDR.0b013e318123fbb8","article-title":"The cannabinoid agi\u00a1onist win55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats","volume":"62","author":"Fernandez-Lopez","year":"2007","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0169-328X(03)00163-3","article-title":"Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia","volume":"114","author":"Mart\u00ednez-Orgado","year":"2003","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.brainres.2010.09.050","article-title":"The cannabinoid receptor agonist WIN 55,212\u20132 reduces the initial cerebral damage after hypoxic-ischemic injury in fetal lambs","volume":"1362","author":"Alonso-Alconada","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0160","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1203\/PDR.0b013e3181894a3e","article-title":"Cannabinoids--can what hurts you make you stronger?","volume":"64","author":"Ferriero","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.brainres.2007.07.076","article-title":"A comparison of the apoptotic effect of \u03949-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex","volume":"1175","author":"Downer","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1471-4159.2002.00961.x","article-title":"Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity","volume":"82","author":"Hansen","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2018.08.014_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0180","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2018.08.014_b0185","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/cbdv.200790147","article-title":"Cannabidiol\u2013recent advances","volume":"4","author":"Mechoulam","year":"2007","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bcp.2018.08.014_b0190","series-title":"Cannabinoids","first-page":"32","article-title":"The pharmacology and therapeutic potential of cannabidiol","author":"Pertwee","year":"2004"},{"key":"10.1016\/j.bcp.2018.08.014_b0195","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.nbd.2009.10.023","article-title":"The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors","volume":"37","author":"Castillo","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.014_b0200","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0205","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fnins.2016.00323","article-title":"Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia","volume":"10","author":"Lafuente","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0210","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1203\/PDR.0b013e3182276b11","article-title":"Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs","volume":"70","author":"Lafuente","year":"2011","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0215","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1871527315666160927110305","article-title":"Neuroprotective effects of cannabidiol in hypoxic ischemic insult. the therapeutic window in newborn mice","volume":"16","author":"Mohammed","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets."},{"key":"10.1016\/j.bcp.2018.08.014_b0220","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.neuropharm.2012.05.034","article-title":"Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function","volume":"63","author":"Pazos","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.014_b0225","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2016.12.017","article-title":"Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke","volume":"116","author":"Cepri\u00e1n","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.014_b0230","first-page":"474","article-title":"Cochrane review: cooling for newborns with hypoxic ischaemic encephalopathy, evidence-based child heal","volume":"5","author":"Jacobs","year":"2010","journal-title":"A Cochrane Rev. J."},{"key":"10.1016\/j.bcp.2018.08.014_b0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/pr.2017.104","article-title":"Cannabidiol reduces lung injury induced by hypoxic-ischemic brain damage in newborn piglets","volume":"82","author":"Arruza","year":"2017","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0240","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/pr.2016.149","article-title":"Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets","volume":"80","author":"Garberg","year":"2016","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0245","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejphar.2016.11.011","article-title":"Anti-excitotoxic effects of cannabidiol are partly mediated by enhancement of NCX2 and NCX3 expression in animal model of cerebral ischemia","volume":"794","author":"Khaksar","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0250","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bph.13368","article-title":"Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPAR\u03b3 and 5-HT 1A receptors","volume":"173","author":"Hind","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0255","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2018.08.014_b0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2011.11.003","article-title":"Genes of early-onset epileptic encephalopathies: from genotype to phenotype","volume":"46","author":"Mastrangelo","year":"2012","journal-title":"Pediatr. Neurol."},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2018.08.014_b0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/epi.12178","article-title":"Opportunity gained, opportunity lost: treating pharmacoresistant epilepsy in children","volume":"54","author":"Donner","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2018.08.014_b0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40263-013-0041-6","article-title":"Treatment of epileptic encephalopathies","volume":"27","author":"McTague","year":"2013","journal-title":"CNS Drugs."},{"key":"10.1016\/j.bcp.2018.08.014_b0275","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1528-1167.2006.00894.x","article-title":"Seizures and antiepileptic drugs: does exposure alter normal brain development?","volume":"47","author":"Marsh","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2018.08.014_b0280","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.braindev.2017.01.006","article-title":"Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy","volume":"39","author":"Moavero","year":"2017","journal-title":"Brain Dev."},{"key":"10.1016\/j.bcp.2018.08.014_b0285","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/NDT.S1668","article-title":"Treatment of Lennox-Gastaut syndrome: overview and recent findings","volume":"4","author":"van Rijckevorsel","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bcp.2018.08.014_b0290","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1212\/WNL.0b013e31826c1b55","article-title":"Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study","volume":"79","author":"Berg","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.bcp.2018.08.014_b0295","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the Treatment of Epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.08.014_b0300","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1093\/jxb\/ern260","article-title":"Phytochemical and genetic analyses of ancient cannabis from Central Asia","volume":"59","author":"Russo","year":"2008","journal-title":"J. Exp. Bot."},{"key":"10.1016\/j.bcp.2018.08.014_b0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1300\/J175v01n01_05","article-title":"The Therapeutic Use of Cannabis sativa (L.) in Arabic Medicine","volume":"1","author":"Lozano","year":"2001","journal-title":"J. Cannabis Ther."},{"key":"10.1016\/j.bcp.2018.08.014_b0310","first-page":"363","article-title":"On the preparations of the indian hemp, or gunjah: cannabis indica their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases","volume":"5","author":"O\u2019Shaughnessy","year":"1843","journal-title":"Prov. Med. J. Retrosp. Med. Sci."},{"key":"10.1016\/j.bcp.2018.08.014_b0315","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejim.2018.01.001","article-title":"Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America","volume":"49","author":"Abuhasira","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.bcp.2018.08.014_b0320","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cpt.115","article-title":"Medicinal chemistry of cannabinoids","volume":"97","author":"Vemuri","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.08.014_b0325","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0024-3205(74)90009-5","article-title":"Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids","volume":"15","author":"Karler","year":"1974","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2018.08.014_b0330","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00413961","article-title":"Effect of cannabidiol and of other cannabis sativa compounds on hippocampal seizure discharges","volume":"28","author":"Izquierdo","year":"1973","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.bcp.2018.08.014_b0335","first-page":"231","article-title":"Anticonvulsant properties of cannabidiol","volume":"8","author":"Turkanis","year":"1974","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0340","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(01)01243-2","article-title":"Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects","volume":"428","author":"Wallace","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0345","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0014-2999(02)02331-2","article-title":"Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity","volume":"452","author":"Wallace","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2018.08.014_b0355","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0091-3057(82)90418-X","article-title":"Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats","volume":"16","author":"Colasanti","year":"1982","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2018.08.014_b0360","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0028-3908(86)90240-6","article-title":"Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol","volume":"25","author":"Karler","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.014_b0365","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1528-1157.1979.tb04816.x","article-title":"The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats","volume":"20","author":"Chiu","year":"1979","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2018.08.014_b0370","doi-asserted-by":"crossref","first-page":"10516","DOI":"10.1038\/s41598-017-10447-2","article-title":"Natural (\u0394\u03949-THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the cannabinoid CB1 receptor","volume":"7","author":"Malyshevskaya","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2018.08.014_b0375","article-title":"Species-specific susceptibility to cannabis-induced convulsions","author":"Whalley","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0380","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bcp.2004.07.007","article-title":"On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures","volume":"68","author":"Lutz","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0385","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.neuron.2006.07.006","article-title":"The endocannabinoid system controls key epileptogenic circuits in the hippocampus","volume":"51","author":"Monory","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2018.08.014_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2018.03.013","article-title":"The psychiatric consequences of cannabinoids","author":"De Aquino","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcp.2018.08.014_b0395","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2018.08.014_b0400","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0405","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bph.12321","article-title":"Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism","volume":"170","author":"Hill","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0410","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1523\/JNEUROSCI.4212-08.2009","article-title":"Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels","volume":"29","author":"Ryan","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0415","doi-asserted-by":"crossref","unstructured":"J.S. Kaplan, N. Stella, W.A. Catterall, R.E. Westenbroek, Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome, (n.d.). doi:10.1073\/pnas.1711351114.","DOI":"10.1073\/pnas.1711351114"},{"key":"10.1016\/j.bcp.2018.08.014_b0420","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0425","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?","volume":"75","author":"Fern\u00e1ndez-Ruiz","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2008.01.001","article-title":"Role of CB<inf>2<\/inf> receptors in neuroprotective effects of cannabinoids","volume":"286","author":"Fern\u00e1ndez-Ruiz","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2018.08.014_b0440","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.220","article-title":"Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome","volume":"4","author":"Rubio","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bcp.2018.08.014_b0445","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2018.08.014_b0450","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuroscience.2010.07.004","article-title":"CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies","volume":"170","author":"Zurolo","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.014_b0455","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.nbd.2013.06.016","article-title":"Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors","volume":"59","author":"Mecha","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.014_b0460","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2018.08.014_b0465","unstructured":"Gupta S, Why I changed my mind on weed, Online: Http:\/\/Www.Cnn.Com\/2013\/08\/08\/Health\/Gupta-Changed-Mind-Marijuana\/, 2013."},{"key":"10.1016\/j.bcp.2018.08.014_b0470","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.bcp.2018.08.014_b0475","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.08.014_b0480","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2215-0366(17)30075-5","article-title":"Can we make cannabis safer?","volume":"4","author":"Englund","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bcp.2018.08.014_b0485","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","article-title":"Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy","volume":"45","author":"Press","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.bcp.2018.08.014_b0490","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","article-title":"Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome","volume":"47","author":"Hussain","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.bcp.2018.08.014_b0495","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1389200217666151210142051","article-title":"Cannabinoids and Cytochrome P450 Interactions","volume":"17","author":"Zendulka","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2018.08.014_b0500","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2018.08.014_b0505","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2018.08.014_b0510","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","article-title":"CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience","volume":"35","author":"Tzadok","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.bcp.2018.08.014_b0515","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.pediatrneurol.2015.02.008","article-title":"Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report","volume":"52","author":"Saade","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.bcp.2018.08.014_b0520","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.bcp.2018.08.014_b0525","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.bcp.2018.08.014_b0530","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.02.009","article-title":"Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome","volume":"71","author":"Kaplan","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.bcp.2018.08.014_b0535","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.yebeh.2018.02.009","article-title":"Cannabidiol for treatment of refractory childhood epilepsies: experience from a single tertiary epilepsy center in Slovenia","volume":"81","author":"Neubauer","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.bcp.2018.08.014_b0540","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Cannabidiol in dravet syndrome study group, trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.08.014_b0545","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2018.08.014_b0550","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"GWPCARE1 Part A Study Group, Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.bcp.2018.08.014_b0555","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.plipres.2013.05.004","article-title":"Cannabinoid receptor signaling in progenitor\/stem cell proliferation and differentiation","volume":"52","author":"Galve-Roperh","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bcp.2018.08.014_b0560","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrn3846","article-title":"Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies","volume":"15","author":"Maccarrone","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0565","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/cercor\/bhu039","article-title":"CB1 Cannabinoid Receptor-Dependent Activation of mTORC1\/Pax6 Signaling Drives Tbr2 Expression and Basal Progenitor Expansion in the Developing Mouse Cortex","volume":"25","author":"D\u00edaz-Alonso","year":"2015","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.bcp.2018.08.014_b0570","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1016\/S0021-9258(20)57315-8","article-title":"The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis (Journal of Biological Chemistry (2007) 282, (23892\u201323898))","volume":"283","author":"Aguado","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.08.014_b0575","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/j.1460-9568.2007.05782.x","article-title":"Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2","volume":"26","author":"Ar\u00e9valo-Mart\u00edn","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063529","article-title":"Activation of type 1 cannabinoid receptor (CB1R) promotes neurogenesis in murine subventricular zone cell cultures","volume":"8","author":"Xapelli","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2018.08.014_b0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2014.00059","article-title":"Modulation of subventricular zone oligodendrogenesis: a role for hemopressin?","volume":"8","author":"Xapelli","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0590","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1523\/JNEUROSCI.5693-09.2010","article-title":"Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice","volume":"30","author":"Gao","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0595","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2018.08.014_b0600","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/bph.12478","article-title":"The cannabinoid CB 2 receptor agonist AM1241 enhances neurogenesis in GFAP\/Gp120 transgenic mice displaying deficits in neurogenesis","volume":"171","author":"Avraham","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0605","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.expneurol.2010.09.003","article-title":"A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats","volume":"226","author":"Solbrig","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bcp.2018.08.014_b0610","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.neuropharm.2017.10.023","article-title":"Monoacylglycerol lipase inhibitor JZL184 prevents HIV-1 gp120-induced synapse loss by altering endocannabinoid signaling","volume":"128","author":"Zhang","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.014_b0615","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.mcn.2008.05.001","article-title":"A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner","volume":"38","author":"Goncalves","year":"2008","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0620","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.nbd.2009.01.014","article-title":"Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis","volume":"34","author":"Marchalant","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.014_b0625","first-page":"1","article-title":"Activation of CB 2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer \u2019 s disease","author":"Wu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0630","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1074\/jbc.M111.291294","article-title":"CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling","volume":"287","author":"Palazuelos","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.08.014_b0635","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/STROKEAHA.116.014793","article-title":"Cannabinoid type-2 receptor drives neurogenesis and improves functional outcome after stroke","volume":"48","author":"Bravo-Ferrer","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.bcp.2018.08.014_b0640","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1523\/JNEUROSCI.5483-10.2011","article-title":"Endocannabinoids Regulate the Migration of Subventricular Zone-Derived Neuroblasts in the Postnatal Brain","volume":"31","author":"Oudin","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.014_b0645","article-title":"In vivo evidence for therapeutic properties of cannabidiol (cbd) for alzheimer\u2019s disease","volume":"820","author":"Watt","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.014_b0650","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:04:57Z","timestamp":1762095897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218303344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":129,"alternative-id":["S0006295218303344"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.08.014","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}